View ValuationBeta Systems Software 将来の成長Future 基準チェック /16Beta Systems Softwareの収益は年間31.7%で減少すると予測されていますが、年間収益は年間8.3%で増加すると予想されています。EPS は年間38.8%で減少すると予想されています。主要情報-31.7%収益成長率-38.80%EPS成長率Capital Markets 収益成長7.2%収益成長率8.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日02 Mar 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 13+ 1 more updateSparta AG, Annual General Meeting, Apr 22, 2026Sparta AG, Annual General Meeting, Apr 22, 2026, at 10:30 W. Europe Standard Time.お知らせ • Feb 09Sparta AG, Annual General Meeting, Mar 18, 2025Sparta AG, Annual General Meeting, Mar 18, 2025, at 11:30 W. Europe Standard Time.お知らせ • Sep 18Diatreme Resources Limited (ASX:DRX) acquired Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million.Diatreme Resources Limited (ASX:DRX) made an offer to acquire Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on February 16, 2024. exchange ratio for the consideration is 1.3319. As of May 21, 2024 minimum tender condition was fulfilled. As of May 24, 2024 Diatreme Resources Limited is encouraging all Metallica shareholders to Accept the Offer and has amassed a 57 per cent stake in Metallica, Turning the deal hostile. Transaction is expected to complete on June 11, 2024. As of announcement on June 3, 2024, the deal is expected to be completed on June 14, 2024. As of July 4, 2024, Diatreme Resources holds 71.28% stake in Metallica Minerals and the offer will get closed on July 9, 2024. As of Diatreme Resources holds 79.67% stake in Metallica Minerals and the offer will get closed on July 23, 2024. Transaction has been approved by Diatreme Resources Limited's Board of director's. Transaction will be completed on August 6, 2024. As on July 24, 2024, Diatreme Resources has now acquired a relevant interest in more than 90% of Metallica Shares and more than 75% of the Metallica Shares that it offered to acquire under the Offer. The Offer is due to close on 6 August 2024 and will not be extended further by Diatreme. Subject to the terms of the Offer, Metallica Shareholders who accept the Offer before the closing date will receive the Offer Consideration within 10 Business Days of acceptance. Given Diatreme’s relevant interest in Metallica is now more than 90%, Diatreme will seek to compulsorily acquire any outstanding Metallica Shares. As on August 16, 2024, Metallica Minerals will be removed from the Official List at the close of trading on Friday, 16 August 2024, following compulsory acquisition of its remaining securities by Diatreme Resources Limited. KPMG Financial Advisory Services (Australia) Pty Limited acted as Financial advisor and Mccullough Robertson Lawyers and GRE Capital Pty Ltd acted as legal advisor to Diatreme Resources Limited (ASX:DRX). Jones Day (Australia) acted as legal advisor to Ilwella Pty Ltd and Market Eye Pty Ltd acted as registrar to Diatreme. Rodd Levy and Jason Jordan of Herbert Smith Freehills acted as legal advisor to Diatreme Resources. Diatreme Resources Limited (ASX:DRX) completed the acquisition of Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on September 18, 2024. As at close of the takeover offer period on 6 August 2024, Diatreme Resources Limited had a relevant interest in 92.7% of Metallica Minerals Limited shares. Following completion of the compulsory acquisition process, Diatreme Resources Limited now has a relevant interest in 100% of Metallica Minerals Limited shares.Reported Earnings • Aug 18First half 2024 earnings released: €1.80 loss per share (vs €2.72 loss in 1H 2023)First half 2024 results: €1.80 loss per share (improved from €2.72 loss in 1H 2023). Net loss: €8.67m (loss narrowed 9.3% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 29Full year 2023 earnings releasedFull year 2023 results: Net loss: €14.7m (loss narrowed 64% from FY 2022).New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.0m (US$95.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€90.0m market cap, or US$95.8m).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$93.0m).Reported Earnings • Aug 03First half 2023 earnings released: €2.72 loss per share (vs €15.73 loss in 1H 2022)First half 2023 results: €2.72 loss per share (improved from €15.73 loss in 1H 2022). Net loss: €9.55m (loss narrowed 70% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 07Full year 2022 earnings releasedFull year 2022 results: Net loss: €40.4m (loss widened €39.9m from FY 2021).Buying Opportunity • May 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €39.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 02First half 2022 earnings releasedFirst half 2022 results: Net income: (down €4.44m from profit in 1H 2021).Reported Earnings • May 04Full year 2021 earnings releasedFull year 2021 results: Revenue: €3.26m (down 46% from FY 2020). Net loss: €507.5k (down 103% from profit in FY 2020).Reported Earnings • Aug 18First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and revenues, although profit margins were improved. First half 2021 results: Revenue: €5.60m (down 1,114% from 1H 2020). Net income: €4.44m (down 51% from 1H 2020). Profit margin: 79% (up from net loss in 1H 2020). The move to profitability was driven by lower revenue.Reported Earnings • May 01Full year 2020 earnings releasedFull year 2020 results: Revenue: €15.9m (up 106% from FY 2019). Net income: €15.9m (up €15.5m from FY 2019).Is New 90 Day High Low • Feb 20New 90-day low: €74.00The company is down 27% from its price of €102 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: €111The company is up 8.0% from its price of €103 on 07 October 2020. The German market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Capital Markets industry, which is up 8.0% over the same period.Is New 90 Day High Low • Sep 26New 90-day low: €96.00The company is down 5.0% from its price of €101 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 8.0% over the same period.お知らせ • Sep 23Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million.Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million on July 27, 2020. Under the terms, the shares will be acquired at a price of €2 per share. The acceptance period runs from September 1, 2020 to September 29, 2020. The management board and supervisory board of 4basebio consider the amount of the offer consideration by the bidder to be appropriate. Thorsten Kuthe, Meike Dresler-Lenz, Stefan Westerheide, Lena Pfeufer and Michael Neises of Heuking Kühn Lüer Wojtek acted as legal advisor to 4basebio AG.業績と収益の成長予測DB:SPT6 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2028102129N/A19/30/20271021310N/A19/30/202693101N/A19/30/20246566N/AN/AN/A6/30/2024-12-14N/AN/AN/A3/31/2024-12-14N/AN/AN/A12/31/2023-12-15N/AN/AN/A9/30/2023-14-17N/AN/AN/A6/30/2023-16-19N/AN/AN/A3/31/2023-27-30N/AN/AN/A12/31/2022-38-40N/AN/AN/A9/30/2022-36-38N/AN/AN/A6/30/2022-34-36N/AN/AN/A3/31/2022-16-18N/AN/AN/A12/31/20212-1N/AN/AN/A9/30/202175N/AN/AN/A6/30/20211211N/AN/AN/A3/31/2021914N/AN/AN/A12/31/2020616N/AN/AN/A9/30/2020111N/AN/AN/A6/30/2020-45N/AN/AN/A3/31/2020-13N/AN/AN/A12/31/201920N/AN/AN/A9/30/201950N/AN/AN/A6/30/20197-1N/AN/AN/A3/31/20198-1N/AN/AN/A12/31/20189-1N/AN/AN/A9/30/2018136N/AN/AN/A6/30/20181814N/AN/AN/A3/31/20181715N/AN/AN/A12/31/20171717N/AN/AN/A9/30/20171213N/AN/AN/A6/30/201789N/AN/AN/A3/31/201787N/AN/AN/A12/31/201676N/AN/AN/A9/30/201644N/AN/AN/A6/30/201612N/AN/AN/A3/31/201686N/AN/AN/A12/31/20151610N/AN/AN/A9/30/20152313N/AN/AN/A6/30/20153016N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SPT6の収益は今後 3 年間で減少すると予測されています (年間-31.7% )。収益対市場: SPT6の収益は今後 3 年間で減少すると予測されています (年間-31.7% )。高成長収益: SPT6の収益は今後 3 年間で減少すると予測されています。収益対市場: SPT6の収益 ( 8.3% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: SPT6の収益 ( 8.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SPT6の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 03:33終値2026/05/20 00:00収益2024/09/30年間収益2024/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Beta Systems Software Aktiengesellschaft 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Adam JakubowskiSMC Research
お知らせ • Mar 13+ 1 more updateSparta AG, Annual General Meeting, Apr 22, 2026Sparta AG, Annual General Meeting, Apr 22, 2026, at 10:30 W. Europe Standard Time.
お知らせ • Feb 09Sparta AG, Annual General Meeting, Mar 18, 2025Sparta AG, Annual General Meeting, Mar 18, 2025, at 11:30 W. Europe Standard Time.
お知らせ • Sep 18Diatreme Resources Limited (ASX:DRX) acquired Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million.Diatreme Resources Limited (ASX:DRX) made an offer to acquire Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on February 16, 2024. exchange ratio for the consideration is 1.3319. As of May 21, 2024 minimum tender condition was fulfilled. As of May 24, 2024 Diatreme Resources Limited is encouraging all Metallica shareholders to Accept the Offer and has amassed a 57 per cent stake in Metallica, Turning the deal hostile. Transaction is expected to complete on June 11, 2024. As of announcement on June 3, 2024, the deal is expected to be completed on June 14, 2024. As of July 4, 2024, Diatreme Resources holds 71.28% stake in Metallica Minerals and the offer will get closed on July 9, 2024. As of Diatreme Resources holds 79.67% stake in Metallica Minerals and the offer will get closed on July 23, 2024. Transaction has been approved by Diatreme Resources Limited's Board of director's. Transaction will be completed on August 6, 2024. As on July 24, 2024, Diatreme Resources has now acquired a relevant interest in more than 90% of Metallica Shares and more than 75% of the Metallica Shares that it offered to acquire under the Offer. The Offer is due to close on 6 August 2024 and will not be extended further by Diatreme. Subject to the terms of the Offer, Metallica Shareholders who accept the Offer before the closing date will receive the Offer Consideration within 10 Business Days of acceptance. Given Diatreme’s relevant interest in Metallica is now more than 90%, Diatreme will seek to compulsorily acquire any outstanding Metallica Shares. As on August 16, 2024, Metallica Minerals will be removed from the Official List at the close of trading on Friday, 16 August 2024, following compulsory acquisition of its remaining securities by Diatreme Resources Limited. KPMG Financial Advisory Services (Australia) Pty Limited acted as Financial advisor and Mccullough Robertson Lawyers and GRE Capital Pty Ltd acted as legal advisor to Diatreme Resources Limited (ASX:DRX). Jones Day (Australia) acted as legal advisor to Ilwella Pty Ltd and Market Eye Pty Ltd acted as registrar to Diatreme. Rodd Levy and Jason Jordan of Herbert Smith Freehills acted as legal advisor to Diatreme Resources. Diatreme Resources Limited (ASX:DRX) completed the acquisition of Metallica Minerals Limited (ASX:MLM) from Ilwella Pty Ltd and Sibelco Asia Pacific Pty Ltd for AUD 28 million on September 18, 2024. As at close of the takeover offer period on 6 August 2024, Diatreme Resources Limited had a relevant interest in 92.7% of Metallica Minerals Limited shares. Following completion of the compulsory acquisition process, Diatreme Resources Limited now has a relevant interest in 100% of Metallica Minerals Limited shares.
Reported Earnings • Aug 18First half 2024 earnings released: €1.80 loss per share (vs €2.72 loss in 1H 2023)First half 2024 results: €1.80 loss per share (improved from €2.72 loss in 1H 2023). Net loss: €8.67m (loss narrowed 9.3% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 29Full year 2023 earnings releasedFull year 2023 results: Net loss: €14.7m (loss narrowed 64% from FY 2022).
New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €90.0m (US$95.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€90.0m market cap, or US$95.8m).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €85.1m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€85.1m market cap, or US$93.0m).
Reported Earnings • Aug 03First half 2023 earnings released: €2.72 loss per share (vs €15.73 loss in 1H 2022)First half 2023 results: €2.72 loss per share (improved from €15.73 loss in 1H 2022). Net loss: €9.55m (loss narrowed 70% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 07Full year 2022 earnings releasedFull year 2022 results: Net loss: €40.4m (loss widened €39.9m from FY 2021).
Buying Opportunity • May 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €39.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 02First half 2022 earnings releasedFirst half 2022 results: Net income: (down €4.44m from profit in 1H 2021).
Reported Earnings • May 04Full year 2021 earnings releasedFull year 2021 results: Revenue: €3.26m (down 46% from FY 2020). Net loss: €507.5k (down 103% from profit in FY 2020).
Reported Earnings • Aug 18First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and revenues, although profit margins were improved. First half 2021 results: Revenue: €5.60m (down 1,114% from 1H 2020). Net income: €4.44m (down 51% from 1H 2020). Profit margin: 79% (up from net loss in 1H 2020). The move to profitability was driven by lower revenue.
Reported Earnings • May 01Full year 2020 earnings releasedFull year 2020 results: Revenue: €15.9m (up 106% from FY 2019). Net income: €15.9m (up €15.5m from FY 2019).
Is New 90 Day High Low • Feb 20New 90-day low: €74.00The company is down 27% from its price of €102 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 13% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: €111The company is up 8.0% from its price of €103 on 07 October 2020. The German market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Capital Markets industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Sep 26New 90-day low: €96.00The company is down 5.0% from its price of €101 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 8.0% over the same period.
お知らせ • Sep 23Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million.Sparta AG (DB:SPT6) made an offer to acquire remaining 95.8% stake in 4basebio AG (XTRA:4BSB) for €92.3 million on July 27, 2020. Under the terms, the shares will be acquired at a price of €2 per share. The acceptance period runs from September 1, 2020 to September 29, 2020. The management board and supervisory board of 4basebio consider the amount of the offer consideration by the bidder to be appropriate. Thorsten Kuthe, Meike Dresler-Lenz, Stefan Westerheide, Lena Pfeufer and Michael Neises of Heuking Kühn Lüer Wojtek acted as legal advisor to 4basebio AG.